Ax­some clears Phase 3 in nar­colep­sy; Nkar­ta eyes $240M raise

Plus, news about AriBio, Fer­rer, Verge Ge­nomics, Ther­at­e­ch­nolo­gies and BioX­cel Ther­a­peu­tics:

Ax­some re­ports late-phase da­ta in nar­colep­sy: The biotech’s AXS-12 (re­box­e­tine) suc­ceed­ed in re­duc­ing cat­a­plexy at­tacks and ex­ces­sive day­time sleepi­ness, among oth­er end­points, com­pared to place­bo in the SYM­PHO­NY tri­al. This “re­sult comes very much in line with our pri­or ex­pec­ta­tions,” Mizuho Se­cu­ri­ties an­a­lysts told in­vestors. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER